Member Info for HighFin1

200 people serving coffee to Novacyt management, 10 people maintaining the coffee machines, 10 people in management drinking the coffee and the other 10 people actually sell a few pcr tests.

They can terminate certain positions (probably the bulk of them administrative) because of the takeover of Southern Cross.

£4m cost savings are significant given the yearly loss of £7 million.

That means that if everything goes according to plan they are left with a £3 million yearly loss.

If the new DYPD assay will generate some extra sales, and if it can get hold of another government contract, they might even achieve break even in H2 2026 or 2027.

Paris, France, and Manchester, UK - 1 June 2026 Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces further proposed changes to its operating cost base.

Following the successful launch of a number of new products over the past 18 months and the recent acquisition of Southern Cross Diagnostics Pty Ltd, the Group is accelerating its plans to focus and streamline its operations and cost base.

The Company announces that it has begun a consultation process with certain members of staff across the Group which may result in a reduction of up to 40% in the Group’s headcount (total headcount as at 26 May 2026 was circa 230). A further announcement will be released in respect of the outcome of the consultation process in due course.

Should the restructuring proceed, the associated labour and non-labour savings are expected to reduce the Group’s annual cash burn by up to circa £4.0m, once all restructuring initiatives are complete. A cash restructuring charge of up to circa £1.0m is expected to be incurred. These numbers are conditional on the consultation process and assume the total reduction of 40%.

That would be a very sustainable pump...

Yes and?

Your main question is: will Novacyt make money on this?

The answer is NO. Because they don't sell the right Ebola test and even if they did, other bigger companies will be first in line.

Great.

But ask yourself the question: will they generate £10.000.000 in sales from the DYPD test (a 50% revenue increase), which is necessary just to wipe out the £7.000.000 yearly loss?

Probably not and when the current <£10 million cash runs out in H2 2027 there WILL BE a placing. They will NOT be able to increase revenue by 50% in a year.

...kgggggk... We are sinking!!

Were are the pump comments??

At least 3 pink cloud posts are needed to keep the share price afloat!

leddachjack comes over as an individual that does not care about company fundamentals, only about how high a group of ******s can pump a stock so he can profit off of them.

take a look at the novacyt 5 year chart and see how many people got tricked in pump and dump schemes.

must have been at least 10.

What "everything else"?

Novacyt is still making an annual loss of £6.000.000 a year and is currently consuming her last cash reserves.

With a cash position of around £10m, this company will not even make it to 2028.

The DYPD assay is nice but may only contribute £1 million a year in peak sales.

It definitely will not wipe out the £6m/year loss.

Don't buy this stock.

Novacyt doesn't even sell the right test for the current Ebola strain, and even if they would, revenue would still be zero because Novacyt doesn't have presence in Afrika (less than 50k revenue/year)

Novacyt will not sell Hantavirus tests.

Novacyt will not sell Ebola tests

Novacyt actually will sell their new DYPD assay but not nearly enough of them to wipe out the £6.000.000 a year loss.

If there is a 60% margin on this assay, Novacyt will have to generate £10.000.000 in revenue from this new assay just to break even.

JUST TO BREAK EVEN. We are not even talking profit here, just breaking even.

Guys get the thought of Novacyt selling Ebola or Hantavirus testing kits out of your head.

YES they have these tests and NO they will not sell them.

Out of all the disease outbreaks that we've had the past 2 years, Mpox/record flu season/heavy Covid season/Ebola/Marburg etcetera.. Novacyt/Primerdesign saw revenue DECLINE in these periods. Not even a tiny piny increase. Zerow.

....kgggggk...

.....Mayday mayday....kggggggk...

...we are sinking....kgggggk... I repeat we are sinking....kgggggk...

I can assure you, Novacyt hasn't sold ANY Hantavirus test kits, nor will they sell ANY Ebola test kits going forward.

It's all f'ucked. It really is. No bright white light in sight, just darkness.

Wow, Novacyt will probably make so much money on this outbreak.

Just like when Mpox was raging in Africa, when Primerdesign revenue actually declined instead of increase.

But you didn't listen did you.

Congrats to the LT holders and the early buyers who sold at 80p

Watch out, don't buy in this dump because you WILL become a bag holder.

I know it's all f'ucked

This crap will dump to 20p before june

Why the decline???

Lyn Rees told yesterday in this interview that Novacyt will sell a lot of Hantavirus test kits in the coming months and that they expect to generate close to £10 million in Profit in 2027:

https://youtu.be/dQw4w9WgXcQ?is=btSyiliQT2P9mrZe

I just came across this interview with Lyn Rees, explaining that Novacyt in on track to deliver a EBITDA of £10 million in 2027 and that they are expecting to generate a lot of revenue from this Hantavirus outbreak

https://youtu.be/dQw4w9WgXcQ?is=fNyrfm3vIsx_BuLP

Please explain to me clearly why this stock should go up.